Cargando…

AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis

Detalles Bibliográficos
Autores principales:	Zhao, Hongli, Zhao, Jue, Hou, Jiapeng, Wang, Siqing, Ding, Yu, Lu, Boxun, Wang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2017
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563284/ https://www.ncbi.nlm.nih.gov/pubmed/28555377 http://dx.doi.org/10.1007/s13238-017-0424-4

Ejemplares similares

Development of an AlphaLISA assay for sensitive and accurate detection of influenza B virus
por: Zong, Huijun, et al.
Publicado: (2023)

Comparison of AlphaLISA and RIA assays for measurement of wool cortisol concentrations
por: Peric, T., et al.
Publicado: (2020)

Rapid, automated, parallel quantitative immunoassays using highly integrated microfluidics and AlphaLISA
por: Tak For Yu, Zeta, et al.
Publicado: (2015)

Rapid and sensitive detection of botulinum toxin type A in complex sample matrices by AlphaLISA
por: Zhang, Liwen, et al.
Publicado: (2022)

Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay
por: Baldo, Barbara, et al.
Publicado: (2018)

Detection of Shiga Toxin 2 Produced by Escherichia coli in Foods Using a Novel AlphaLISA
por: Armstrong, Cheryl M., et al.
Publicado: (2018)

Development of a Cell-Based AlphaLISA Assay for High-Throughput Screening for Small Molecule Proteasome Modulators
por: Staerz, Sophia D., et al.
Publicado: (2023)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid
por: Gorshkov, Kirill, et al.
Publicado: (2020)

Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid
por: Gorshkov, Kirill, et al.
Publicado: (2020)

Characterization of the Humoral Immune Response to Porcine Epidemic Diarrhea Virus Infection under Experimental and Field Conditions Using an AlphaLISA Platform
por: Kimpston-Burkgren, Kay, et al.
Publicado: (2020)

Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
por: Hanson, Quinlin M., et al.
Publicado: (2020)

Targeting ACE2–RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay
por: Hanson, Quinlin M., et al.
Publicado: (2020)

Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers
por: Prabhu, Lakshmi, et al.
Publicado: (2017)

Associations of sleep characteristics with alpha‐synuclein in cerebrospinal fluid in older adults
por: Wang, Xiao‐Tong, et al.
Publicado: (2020)

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders
por: Agnello, Luisa, et al.
Publicado: (2022)

Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson’s Disease
por: Menéndez-González, Manuel, et al.
Publicado: (2018)

Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels
por: Ibanez, Laura, et al.
Publicado: (2017)

Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9–Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA
por: Pulido-Olmo, Helena, et al.
Publicado: (2017)

Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies
por: Perra, Daniela, et al.
Publicado: (2021)

Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease
por: Maass, Fabian, et al.
Publicado: (2020)

Transmission of alpha-synuclein in Parkinson’s disease
por: Lee, Virginia M-Y
Publicado: (2013)

Alpha-synuclein spreading in Parkinson’s disease
por: Recasens, Ariadna, et al.
Publicado: (2014)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease
por: Cersosimo, Maria Graciela
Publicado: (2015)

Cerebrospinal Fluid Amyloid β(1-42), Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease
por: Kang, Ju-Hee
Publicado: (2016)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
por: Dolatshahi, Mahsa, et al.
Publicado: (2018)

Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay
por: Cariulo, Cristina, et al.
Publicado: (2019)

Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
por: Gómez-Benito, Mónica, et al.
Publicado: (2020)

Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021)

New Perspectives on Roles of Alpha-Synuclein in Parkinson’s Disease
por: Zhang, Guoxin, et al.
Publicado: (2018)

SUMOylation of Alpha-Synuclein Influences on Alpha-Synuclein Aggregation Induced by Methamphetamine
por: Zhu, Lin-nan, et al.
Publicado: (2018)

Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease
por: Chang, Chun-Wei, et al.
Publicado: (2020)

Toxicity of extracellular alpha-synuclein is independent of intracellular alpha-synuclein
por: Dening, Yanina, et al.
Publicado: (2022)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
por: Maraganore, Demetrius M.
Publicado: (2011)

Interaction between Neuromelanin and Alpha-Synuclein in Parkinson’s Disease
por: Xu, Shengli, et al.
Publicado: (2015)

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
por: George, Sonia, et al.
Publicado: (2015)

The Identification of Alpha-Synuclein as the First Parkinson Disease Gene
por: Nussbaum, Robert L.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_opfbuk23dbk4vv568e2ri9j537